Cargando…

Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial

BACKGROUND: Health outcomes for people treated for type 2 diabetes could be substantially improved in sub-Saharan Africa. Failure to take medicine regularly to treat diabetes has been identified as a major problem. Resources to identify and support patients who are not making the best use of medicin...

Descripción completa

Detalles Bibliográficos
Autores principales: Farmer, Andrew, Bobrow, Kirsty, Leon, Natalie, Williams, Nicola, Phiri, Enita, Namadingo, Hazel, Cooper, Sara, Prince, John, Crampin, Amelia, Besada, Donela, Daviaud, Emmanuelle, Yu, Ly-Mee, Ngoma, Jonathan, Springer, David, Pauly, Bruno, Norris, Shane, Tarassenko, Lionel, Nyirenda, Moffat, Levitt, Naomi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: JMIR Publications 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592392/
https://www.ncbi.nlm.nih.gov/pubmed/31199346
http://dx.doi.org/10.2196/12377
_version_ 1783429880202919936
author Farmer, Andrew
Bobrow, Kirsty
Leon, Natalie
Williams, Nicola
Phiri, Enita
Namadingo, Hazel
Cooper, Sara
Prince, John
Crampin, Amelia
Besada, Donela
Daviaud, Emmanuelle
Yu, Ly-Mee
Ngoma, Jonathan
Springer, David
Pauly, Bruno
Norris, Shane
Tarassenko, Lionel
Nyirenda, Moffat
Levitt, Naomi
author_facet Farmer, Andrew
Bobrow, Kirsty
Leon, Natalie
Williams, Nicola
Phiri, Enita
Namadingo, Hazel
Cooper, Sara
Prince, John
Crampin, Amelia
Besada, Donela
Daviaud, Emmanuelle
Yu, Ly-Mee
Ngoma, Jonathan
Springer, David
Pauly, Bruno
Norris, Shane
Tarassenko, Lionel
Nyirenda, Moffat
Levitt, Naomi
author_sort Farmer, Andrew
collection PubMed
description BACKGROUND: Health outcomes for people treated for type 2 diabetes could be substantially improved in sub-Saharan Africa. Failure to take medicine regularly to treat diabetes has been identified as a major problem. Resources to identify and support patients who are not making the best use of medicine in low- and middle-income settings are scarce. Mobile phones are widely available in these settings, including among people with diabetes; linked technologies, such as short message service (SMS) text messaging, have shown promise in delivering low-cost interventions efficiently. However, evidence showing that these interventions will work when carried out at a larger scale and measuring the extent to which they will improve health outcomes when added to usual care is limited. OBJECTIVE: The objective of this trial is to test the effectiveness of sending brief, automated SMS text messages for improving health outcomes and medication adherence in patients with type 2 diabetes compared to an active control. METHODS: We will carry out a randomized trial recruiting from clinics in two contrasting settings in sub-Saharan Africa: Cape Town, South Africa, and Lilongwe, Malawi. Intervention messages will advise people about the benefits of their diabetes treatment and offer motivation and encouragement around lifestyle and use of medication. We allocated patients, using randomization with a minimization algorithm, to receive either three to four intervention messages per week or non-health-related messages every 6 weeks. We will follow up with participants for 12 months, measuring important risk factors for poor health outcomes and complications in diabetes. This will enable us to estimate potential health benefits, including the primary outcome of hemoglobin A(1c) (HbA(1c)) levels as a marker for long-term blood glucose control and a secondary outcome of blood pressure control. We will record the costs of performing these activities and estimate cost-effectiveness. We will also use process evaluation to capture the collection of medication and assess the reception of the intervention by participants and health care workers. RESULTS: Recruitment to the trial began in September 2016 and follow-up of participants was completed in October 2018. Data collection from electronic health records and other routinely collected sources is continuing. The database lock is anticipated in June 2019, followed by analysis and disclosing of group allocation. CONCLUSIONS: The knowledge gained from this study will have wide applications and advance the evidence base for effectiveness of mobile phone-based, brief text messaging on clinical outcomes and in large-scale, operational settings. It will provide evidence for cost-effectiveness and acceptability that will further inform policy development and decision making. We will work with a wide network that includes patients, clinicians, academics, industry, and policy makers to help us identify opportunities for informing people about the work and raise awareness of what is being developed and studied. TRIAL REGISTRATION: ISRCTN Registry ISRCTN70768808; http://www.isrctn.com/ISRCTN70768808 (Archived by WebCite at http://www.webcitation.org/786316Zqk) INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/12377
format Online
Article
Text
id pubmed-6592392
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher JMIR Publications
record_format MEDLINE/PubMed
spelling pubmed-65923922019-07-17 Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial Farmer, Andrew Bobrow, Kirsty Leon, Natalie Williams, Nicola Phiri, Enita Namadingo, Hazel Cooper, Sara Prince, John Crampin, Amelia Besada, Donela Daviaud, Emmanuelle Yu, Ly-Mee Ngoma, Jonathan Springer, David Pauly, Bruno Norris, Shane Tarassenko, Lionel Nyirenda, Moffat Levitt, Naomi JMIR Res Protoc Protocol BACKGROUND: Health outcomes for people treated for type 2 diabetes could be substantially improved in sub-Saharan Africa. Failure to take medicine regularly to treat diabetes has been identified as a major problem. Resources to identify and support patients who are not making the best use of medicine in low- and middle-income settings are scarce. Mobile phones are widely available in these settings, including among people with diabetes; linked technologies, such as short message service (SMS) text messaging, have shown promise in delivering low-cost interventions efficiently. However, evidence showing that these interventions will work when carried out at a larger scale and measuring the extent to which they will improve health outcomes when added to usual care is limited. OBJECTIVE: The objective of this trial is to test the effectiveness of sending brief, automated SMS text messages for improving health outcomes and medication adherence in patients with type 2 diabetes compared to an active control. METHODS: We will carry out a randomized trial recruiting from clinics in two contrasting settings in sub-Saharan Africa: Cape Town, South Africa, and Lilongwe, Malawi. Intervention messages will advise people about the benefits of their diabetes treatment and offer motivation and encouragement around lifestyle and use of medication. We allocated patients, using randomization with a minimization algorithm, to receive either three to four intervention messages per week or non-health-related messages every 6 weeks. We will follow up with participants for 12 months, measuring important risk factors for poor health outcomes and complications in diabetes. This will enable us to estimate potential health benefits, including the primary outcome of hemoglobin A(1c) (HbA(1c)) levels as a marker for long-term blood glucose control and a secondary outcome of blood pressure control. We will record the costs of performing these activities and estimate cost-effectiveness. We will also use process evaluation to capture the collection of medication and assess the reception of the intervention by participants and health care workers. RESULTS: Recruitment to the trial began in September 2016 and follow-up of participants was completed in October 2018. Data collection from electronic health records and other routinely collected sources is continuing. The database lock is anticipated in June 2019, followed by analysis and disclosing of group allocation. CONCLUSIONS: The knowledge gained from this study will have wide applications and advance the evidence base for effectiveness of mobile phone-based, brief text messaging on clinical outcomes and in large-scale, operational settings. It will provide evidence for cost-effectiveness and acceptability that will further inform policy development and decision making. We will work with a wide network that includes patients, clinicians, academics, industry, and policy makers to help us identify opportunities for informing people about the work and raise awareness of what is being developed and studied. TRIAL REGISTRATION: ISRCTN Registry ISRCTN70768808; http://www.isrctn.com/ISRCTN70768808 (Archived by WebCite at http://www.webcitation.org/786316Zqk) INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/12377 JMIR Publications 2019-05-30 /pmc/articles/PMC6592392/ /pubmed/31199346 http://dx.doi.org/10.2196/12377 Text en ©Andrew Farmer, Kirsty Bobrow, Natalie Leon, Nicola Williams, Enita Phiri, Hazel Namadingo, Sara Cooper, John Prince, Amelia Crampin, Donela Besada, Emmanuelle Daviaud, Ly-Mee Yu, Jonathan Ngoma, David Springer, Bruno Pauly, Shane Norris, Lionel Tarassenko, Moffat Nyirenda, Naomi Levitt. Originally published in JMIR Research Protocols (http://www.researchprotocols.org), 30.05.2019. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work, first published in JMIR Research Protocols, is properly cited. The complete bibliographic information, a link to the original publication on http://www.researchprotocols.org, as well as this copyright and license information must be included.
spellingShingle Protocol
Farmer, Andrew
Bobrow, Kirsty
Leon, Natalie
Williams, Nicola
Phiri, Enita
Namadingo, Hazel
Cooper, Sara
Prince, John
Crampin, Amelia
Besada, Donela
Daviaud, Emmanuelle
Yu, Ly-Mee
Ngoma, Jonathan
Springer, David
Pauly, Bruno
Norris, Shane
Tarassenko, Lionel
Nyirenda, Moffat
Levitt, Naomi
Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial
title Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial
title_full Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial
title_fullStr Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial
title_full_unstemmed Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial
title_short Mobile Messaging Support Versus Usual Care for People With Type 2 Diabetes on Glycemic Control: Protocol for a Multicenter Randomized Controlled Trial
title_sort mobile messaging support versus usual care for people with type 2 diabetes on glycemic control: protocol for a multicenter randomized controlled trial
topic Protocol
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6592392/
https://www.ncbi.nlm.nih.gov/pubmed/31199346
http://dx.doi.org/10.2196/12377
work_keys_str_mv AT farmerandrew mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT bobrowkirsty mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT leonnatalie mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT williamsnicola mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT phirienita mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT namadingohazel mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT coopersara mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT princejohn mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT crampinamelia mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT besadadonela mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT daviaudemmanuelle mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT yulymee mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT ngomajonathan mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT springerdavid mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT paulybruno mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT norrisshane mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT tarassenkolionel mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT nyirendamoffat mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial
AT levittnaomi mobilemessagingsupportversususualcareforpeoplewithtype2diabetesonglycemiccontrolprotocolforamulticenterrandomizedcontrolledtrial